Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities
Getty Images
January 6, 2021 Hologic, Inc., a global leader in women s health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments.
“Acquiring Biotheranostics enables us to jump-start our entry into a large, fast-growing oncology adjacency that fits perfectly with our broader corporate focus and passion for women’s health,” said Kevin Thornal, Hologic’s Division President, Diagnostics. “Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to accelerate growth, he
January 7, 2021 at 11:30 am by Devanshi Tomar
As the next step in the COVID-19 testing program on campus, members of the COVID-19 Response Team recently established a Clinical Laboratory Improvement Amendments-certified laboratory â an on-campus lab approved for conducting COVID-19 diagnostic tests. The lab allows for coordination of patient sample acquisition of tests, testing logistics, case management and contact tracing efforts.Â
Dr. Jose Carlos Ponce Rojas, a postdoctoral scholar in MCDB, working with samples under a fume hood. Courtesy of Stuart Feinstein
The COVID-19 Response Team includes faculty, administrators and staff on campus. Among the most notable is Professor Carolina Arias, who initiated the on-campus COVID-19 laboratory and has been instrumental in all aspects of its development, according to Stuart Feinstein, another leader in the initiation and integration of the laboratory who joined Sept. 1. Â
OncoDNA Announces Expansion of Its Services Into the United States
The theranostic and genomic company signs subcontract service agreement with HalioDx s CLIA-certified laboratory in Richmond, Virginia
OncoDNA, a theranostic and genomic company specializing in precision oncology, has announced today that it has signed a subcontract service agreement with HalioDx s U.S.-based CLIA-certified laboratory located in Richmond, Virginia. This agreement will enable OncoDNA to expand its unique offering of services to biopharmaceutical companies and research institutions in North America.
OncoDNA has a proven track record in supporting the development of personalized cancer therapies. Its portfolio includes a series of comprehensive molecular diagnostic tests on both solid and liquid biopsies. Combined with an advanced bioinformatic technology, OncoDNA s diagnostic tests offer a unique solution to the US biopharmaceutical industry.
Crawford among counties receiving rapid antigen test card distributions meadvilletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from meadvilletribune.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
The Food and Drug Administration (FDA or the Agency) spent the remaining weeks of 2020 issuing Emergency Use Authorizations (EUAs) for the first over-the-counter (OTC) COVID-19 test to be performed at home and the first OTC home sample collection kit for COVID-19 testing, as well as additional prescription at-home tests and sample collection kits. These newly authorized testing options are expected to help address the critical public health need for additional COVID-19 test capacity. FDA’s authorization of these new EUAs also makes good on promises the Agency made to prioritize its review of rapid and at-home test solutions.